Galibier Capital Management’s AstraZeneca AZN Stock Holding History

Galibier Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,817	Closed	-$1.57M	–	41
2022 Q1	$1.57M	Hold	11,817	–	–	0.21%	22
2021 Q4	$1.38M	Sell	11,817 -2,742	-19%	-$323K	0.2%	22
2021 Q3	$1.75M	Sell	14,559 -100	-0.7%	-$11.6K	0.24%	19
2021 Q2	$1.76M	Sell	14,659 -117	-0.8%	-$12.8K	0.24%	20
2021 Q1	$1.47M	Hold	14,776	–	–	0.22%	22
2020 Q4	$1.48M	Buy	14,776 +2,250	+18%	+$238K	0.26%	20
2020 Q3	$1.37M	Sell	12,526 -129,048	-91%	-$14.4M	0.32%	20
2020 Q2	$15M	Buy	141,574 +3,518	+3%	+$363K	4.79%	8
2020 Q1	$12.3M	Sell	138,056 -40,829	-23%	-$3.84M	5.37%	7
2019 Q4	$17.8M	Buy	178,885 +150,305	+526%	+$14.2M	5.66%	7
2019 Q3	$2.55M	Buy	28,580 +5,692	+25%	+$494K	1.01%	17
2019 Q2	$1.89M	Buy	+22,888	New	+$1.79M	0.86%	25

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Galibier Capital Management's AZN Position: Q2 2022 in Review

Galibier Capital Management sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 11,817 shares — an estimated $1.57M sold.

Galibier Capital Management first reported a position in AZN in Q2 2019 and held it in 12 quarters. The position peaked at $17.8M in Q4 2019. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Galibier Capital Management reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Galibier Capital Management sold 11,817 AstraZeneca shares in Q2 2022, an estimated $1.57M.
Galibier Capital Management first reported a position in AstraZeneca in Q2 2019 and held it in 12 quarters.
Galibier Capital Management's AstraZeneca position peaked at $17.8M in Q4 2019.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Galibier Capital Management's 13F filing for Q2 2022, filed 15 Jul 2022.